用EGFR-TKIs治疗的EGFR突变NSCLC中PD-L1表达和间歇性肺病风险之间的关联
Yutaka Takahara1, Ryudai Abe2, Sumito Nagae2
1Department of Respiratory Medicine, Kanazawa Medical University, Ishikawa, Japan takahara@kanazawa-med.ac.jp.
In vivo (Athens, Greece)
|January 2, 2026
概括
No abstract available in PubMed .
更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
11.0K
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
4.5K
